Jacobio Pharmaceuticals Group Co., Ltd. (HK:1167)
:1167
Want to see HK:1167 full AI Analyst Report?
Top Page
Jacobio Pharmaceuticals Group Co., Ltd.
(1167)
Select Model
Select Model
Rating:46Neutral
Price Target:
HK$5.00
▼(-37.97% Downside)
Action:Upgraded
Date:04/29/26
The score is primarily held down by weak financial performance—sharp revenue contraction, ongoing losses, and sustained negative free cash flow—partially offset by manageable leverage. Technicals are mixed/neutral with some intermediate support but longer-term resistance, and valuation offers limited support given the negative P/E and no dividend yield data.
Positive Factors
Manageable leverage
Low debt relative to equity gives Jacobio structural financial flexibility to fund ongoing R&D and milestone-driven programs without immediate heavy interest burdens. For a clinical-stage biotech, manageable leverage lowers near-term refinancing pressure and preserves optionality for partnerships or selective capital raises over months.
Negative Factors
Severe revenue decline
A c.74% year-over-year revenue drop is a material structural setback for a clinical-stage firm that relies on partner payments and milestone timing. Sustained top-line weakness undermines internal funding capacity, raises dependency on external capital, and materially increases execution risk for ongoing programs over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable leverage
Low debt relative to equity gives Jacobio structural financial flexibility to fund ongoing R&D and milestone-driven programs without immediate heavy interest burdens. For a clinical-stage biotech, manageable leverage lowers near-term refinancing pressure and preserves optionality for partnerships or selective capital raises over months.
Read all positive factors
Jacobio Pharmaceuticals Group Co., Ltd. (1167) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$4.20B
Dividend YieldN/A
Average Volume (3M)7.94M
Price to Earnings (P/E)―
Beta (1Y)1.03
Revenue Growth-65.87%
EPS Growth6.71%
CountryHK
Employees257
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.19
Shares Outstanding791,755,070
10 Day Avg. Volume5,388,349
30 Day Avg. Volume7,936,853
Financial Highlights & Ratios
PEG Ratio3.12
Price to Book (P/B)5.75
Price to Sales (P/S)84.99
P/FCF Ratio-23.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$11.00Price Target Upside36.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.4
Revenue Forecast (FY)HK$723.51M
Jacobio Pharmaceuticals Group Co., Ltd. Business Overview & Revenue Model
Company Description
Jacobio Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. The company's lead drug development programs include two clinical-stage allosteric Src homology r...
How the Company Makes Money
Jacobio Pharmaceuticals generally makes money through (1) collaboration and licensing arrangements, where it grants partners rights to develop and/or commercialize specific drug candidates in certain territories in exchange for upfront payments, d...
Jacobio Pharmaceuticals Group Co., Ltd. Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
62
Positive
Cash Flow
30
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 52.14M | 155.71M | 63.52M | 95.75M | 152.81M |
| Gross Profit | 29.35M | 155.71M | 3.20M | 12.63M | 12.83M |
| EBITDA | -143.46M | -192.36M | -325.73M | -355.80M | -289.83M |
| Net Income | -142.20M | -155.71M | -359.12M | -371.86M | -301.19M |
Balance Sheet | |||||
| Total Assets | 1.30B | 1.36B | 1.46B | 1.57B | 1.72B |
| Cash, Cash Equivalents and Short-Term Investments | 1.13B | 1.17B | 1.15B | 1.28B | 1.54B |
| Total Debt | 165.24M | 152.08M | 209.91M | 147.79M | 6.81M |
| Total Liabilities | 533.92M | 435.99M | 387.11M | 292.12M | 84.75M |
| Stockholders Equity | 770.96M | 923.18M | 1.07B | 1.28B | 1.64B |
Cash Flow | |||||
| Free Cash Flow | -187.27M | -86.21M | -402.86M | -308.92M | -158.63M |
| Operating Cash Flow | -186.20M | -74.12M | -364.20M | -292.42M | -147.49M |
| Investing Cash Flow | -138.63M | 256.22M | -48.00M | -686.32M | 161.67M |
| Financing Cash Flow | 45.20M | 21.28M | 246.28M | -9.85M | 109.06M |
Jacobio Pharmaceuticals Group Co., Ltd. Technical Analysis
Negative
8.06
Price Trends
6.81
Negative
6.67
Negative
7.53
Negative
Market Momentum
-0.47
Positive
25.98
Positive
8.05
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1167, the sentiment is Negative. The current price of 8.06 is above the 20-day moving average (MA) of 6.32, above the 50-day MA of 6.81, and above the 200-day MA of 7.53, indicating a bearish trend. The MACD of -0.47 indicates Positive momentum. The RSI at 25.98 is Positive, neither overbought nor oversold. The STOCH value of 8.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1167.
Jacobio Pharmaceuticals Group Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | HK$4.36B | 2.00 | 2.04% | ― | 1117.02% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$8.33B | -15.87 | -6.26% | ― | -11.65% | -169.40% | |
50 Neutral | HK$12.15B | -15.04 | -64.19% | ― | -33.37% | -344.90% | |
46 Neutral | HK$4.20B | -12.96 | -17.64% | ― | -65.87% | 6.71% | |
46 Neutral | HK$2.89B | -8.92 | -26.73% | ― | 14.59% | 22.41% | |
44 Neutral | HK$14.37B | -6.78 | -123.74% | ― | -41.32% | -159.81% |
* Healthcare Sector Average
HK:1167
Jacobio Pharmaceuticals Group Co., Ltd.
5.30
0.49
10.19%
HK:6996
Antengene Corporation Limited
4.56
0.67
17.22%
HK:6998
Genor Biopharma Holdings Limited
2.13
-0.55
-20.52%
HK:9966
Alphamab Oncology
8.80
-0.18
-2.00%
HK:2616
CStone Pharmaceuticals
7.87
4.15
111.56%
HK:6855
Ascentage Pharma Group International
40.34
-8.41
-17.25%
Jacobio Pharmaceuticals Group Co., Ltd. Corporate Events
Jacobio Boosts Share Buybacks and Liquidity as Oncology Pipeline Advances
May 18, 2026
Jacobio Pharmaceuticals has been steadily repurchasing its own shares under an existing mandate, accumulating 7,47,800 treasury shares at a total cost of about HK$34.17 million. The board argues that the current share price undervalues the company...
Jacobio Pharmaceuticals Sets 2026 AGM, Seeks Fresh Share Issuance Mandate
Apr 24, 2026
Jacobio Pharmaceuticals has called its 2026 annual general meeting for June 5, 2026, in Beijing, where shareholders will review and adopt the company’s audited financial statements and directors’ and auditor’s reports for the yea...
Jacobio Secures US$100 Million Upfront From AstraZeneca for Pan-KRAS Cancer Drug
Mar 30, 2026
Jacobio Pharmaceuticals has received a US$100 million upfront payment from AstraZeneca under their license and collaboration agreement for the pan-KRAS inhibitor JAB-23E73. The inflow significantly strengthens Jacobio’s cash reserves and is ...
Jacobio Wins China KRAS Drug Approval and Strikes US$2 Billion AstraZeneca Deal
Mar 10, 2026
Jacobio reported significant advances in its oncology pipeline, highlighted by Chinese regulatory approval of its KRAS G12C inhibitor glecirasib as a second-line monotherapy for NSCLC and its inclusion in the National Reimbursement Drug List. The ...
Jacobio Pharmaceuticals Sets March Board Meeting to Approve 2025 Annual Results
Feb 26, 2026
Jacobio Pharmaceuticals Group Co., Ltd. has scheduled a board meeting for March 10, 2026, to review and approve the annual results for the year ended December 31, 2025, and to authorize their publication. The meeting signals the forthcoming disclo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.